open access

Vol 28, No 6 (2021)
Review Article
Submitted: 2021-10-30
Accepted: 2021-11-28
Published online: 2021-12-09
Get Citation

Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure

Michał Tkaczyszyn12, Tomasz Skrzypczak3, Jakub Michałowicz3, Piotr Ponikowski12, Ewa A. Jankowska12
·
Pubmed: 34897633
·
Cardiol J 2021;28(6):962-969.
Affiliations
  1. Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland
  2. Institute of Heart Diseases, University Hospital, Wroclaw, Poland
  3. Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland

open access

Vol 28, No 6 (2021)
Review articles — Clinical cardiology
Submitted: 2021-10-30
Accepted: 2021-11-28
Published online: 2021-12-09

Abstract

Acute heart failure (AHF) syndromes are among the most frequent causes of hospitalization in the elderly and put a heavy financial burden on healthcare systems, mainly due to high early readmission rates. The understanding of AHF has evolved over the years from a significant hemodynamic failure to a multi-organ disease in the course of which peripheral mechanisms such as dysregulated cardiorenal axis or inflammation also play essential roles. A few available observational studies investigating iron deficiency (ID) in patients hospitalized for AHF indicate that this comorbidity is more prevalent than in chronic heart failure, and iron status presents some dynamics in these subjects. ID in AHF predicts increased mortality, greater risk for early readmission and is related to prolonged hospitalization. This paper reviews the results of the first multicenter, double-blind, randomized clinical trial on ferric carboxymaltose in patients who were stabilized after an episode of AHF who had concomitant ID (AFFIRM-AHF), and potential pathophysiological links between dysregulated iron status and AHF syndromes are discussed.

Abstract

Acute heart failure (AHF) syndromes are among the most frequent causes of hospitalization in the elderly and put a heavy financial burden on healthcare systems, mainly due to high early readmission rates. The understanding of AHF has evolved over the years from a significant hemodynamic failure to a multi-organ disease in the course of which peripheral mechanisms such as dysregulated cardiorenal axis or inflammation also play essential roles. A few available observational studies investigating iron deficiency (ID) in patients hospitalized for AHF indicate that this comorbidity is more prevalent than in chronic heart failure, and iron status presents some dynamics in these subjects. ID in AHF predicts increased mortality, greater risk for early readmission and is related to prolonged hospitalization. This paper reviews the results of the first multicenter, double-blind, randomized clinical trial on ferric carboxymaltose in patients who were stabilized after an episode of AHF who had concomitant ID (AFFIRM-AHF), and potential pathophysiological links between dysregulated iron status and AHF syndromes are discussed.

Get Citation

Keywords

acute heart failure, cardiac decompensation, iron deficiency, ferric carboxymaltose

About this article
Title

Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure

Journal

Cardiology Journal

Issue

Vol 28, No 6 (2021)

Article type

Review Article

Pages

962-969

Published online

2021-12-09

Page views

7380

Article views/downloads

778

DOI

10.5603/CJ.a2021.0165

Pubmed

34897633

Bibliographic record

Cardiol J 2021;28(6):962-969.

Keywords

acute heart failure
cardiac decompensation
iron deficiency
ferric carboxymaltose

Authors

Michał Tkaczyszyn
Tomasz Skrzypczak
Jakub Michałowicz
Piotr Ponikowski
Ewa A. Jankowska

References (50)
  1. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997; 157(1): 99–104.
  2. Chioncel O, Mebazaa A, Maggioni AP, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017; 19(10): 1242–1254.
  3. Dharmarajan K, Hsieh A, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013; 309(4): 355.
  4. Tymińska A, Ozierański K, Grabowski M, et al. Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure. Cardiol J. 2020; 27(5): 625–632.
  5. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009; 360(14): 1418–1428.
  6. Yancy CW. Acute heart failure: searching for a new evident truth. J Am Coll Cardiol. 2017; 69(11): 1420–1423.
  7. Cotter G, Felker GM, Adams KF, et al. The pathophysiology of acute heart failure--is it all about fluid accumulation? Am Heart J. 2008; 155(1): 9–18.
  8. Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol. 2014; 64(13): 1388–1400.
  9. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297(17): 1883–1891.
  10. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011; 365(1): 32–43.
  11. Packer M, O'Connor C, McMurray JJV, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017; 376(20): 1956–1964.
  12. Metra M, Teerlink JR, Cotter G, et al. Effects of Serelaxin in Patients with Acute Heart Failure. N Engl J Med. 2019; 381(8): 716–726.
  13. Bhatt D, Szarek M, Steg P, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021; 384(2): 117–128.
  14. Njoroge JN, Teerlink JR. Pathophysiology and therapeutic approaches to acute decompensated heart failure. Circ Res. 2021; 128(10): 1468–1486.
  15. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010; 31(15): 1872–1880.
  16. Jankowska EA, Kasztura M, Sokolski M, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014; 35(36): 2468–2476.
  17. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013; 165(4): 575–582.e3.
  18. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361(25): 2436–2448.
  19. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015; 36(11): 657–668.
  20. van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017; 136(15): 1374–1383.
  21. Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016; 18(7): 786–795.
  22. Cohen-Solal A, Damy T, Terbah M, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail. 2014; 16(9): 984–991.
  23. Núñez J, García-Blas S, Comín-Colet J, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016; 18(7): 798–802.
  24. Van Aelst LNL, Abraham M, Sadoune M, et al. Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up. Eur J Heart Fail. 2017; 19(8): 1075–1076.
  25. Beale A, Carballo D, Stirnemann J, et al. Iron deficiency in acute decompensated heart failure. J Clin Med. 2019; 8(10): 1569.
  26. Beattie JM, Khatib R, Phillips CJ, et al. Iron deficiency in 78 805 people admitted with heart failure across England: a retrospective cohort study. Open Heart. 2020; 7(1): e001153.
  27. Jacob J, Miró Ò, Ferre C, et al. Iron deficiency and safety of ferric carboxymaltose in patients with acute heart failure. AHF-ID study. Int J Clin Pract. 2020; 74(10): e13584.
  28. Yeo TJ, Yeo PS, Hadi FA, et al. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). ESC Heart Fail. 2018; 5(2): 344–353.
  29. Ponikowski P, Kirwan BA, Anker SD, et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. Eur J Heart Fail. 2019; 21(12): 1651–1658.
  30. Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020; 396(10266): 1895–1904.
  31. Jankowska EA, Kirwan BA, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021 [Epub ahead of print]: 3011–3020.
  32. McEwan P, Ponikowski P, Davis JA, et al. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF. Eur J Heart Fail. 2021; 23(10): 1687–1697.
  33. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contributio. Eur Heart J. 2021; 42(36): 3599–726.
  34. Dev S, Babitt JL. Overview of iron metabolism in health and disease. Hemodial Int. 2017; 21 Suppl 1: S6–SS20.
  35. Cairo CW, Mirchev R, Golan DE. Cytoskeletal regulation couples LFA-1 conformational changes to receptor lateral mobility and clustering. Immunity. 2006; 25(2): 297–308.
  36. Ponka P. Cell biology of heme. Am J Med Sci. 1999; 318(4): 241–256.
  37. Mettauer B, Zoll J, Garnier A, et al. Heart failure: a model of cardiac and skeletal muscle energetic failure. Pflugers Arch. 2006; 452(6): 653–666.
  38. Neubauer S. The failing heart -- an engine out of fuel. N Engl J Med. 2007; 356(11): 1140–1151.
  39. Rosano GMc, Vitale C. Metabolic modulation of cardiac metabolism in heart failure. Card Fail Rev. 2018; 4(2): 99–103.
  40. Tuunanen H, Knuuti J. Metabolic remodelling in human heart failure. Cardiovasc Res. 2011; 90(2): 251–257.
  41. Recchia FA, McConnell PI, Bernstein RD, et al. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res. 1998; 83(10): 969–979.
  42. Leszek P, Sochanowicz B, Szperl M, et al. Myocardial iron homeostasis in advanced chronic heart failure patients. Int J Cardiol. 2012; 159(1): 47–52.
  43. Tkaczyszyn M, Drozd M, Węgrzynowska-Teodorczyk K, et al. Depleted iron stores are associated with inspiratory muscle weakness independently of skeletal muscle mass in men with systolic chronic heart failure. J Cachexia Sarcopenia Muscle. 2018; 9(3): 547–556.
  44. Stugiewicz M, Tkaczyszyn M, Kasztura M, et al. The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail. 2016; 18(7): 762–773.
  45. Tkaczyszyn M, Comín-Colet J, Voors AA, et al. Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. Eur J Heart Fail. 2021; 23(10): 1677–1686.
  46. Charles-Edwards G, Amaral N, Sleigh A, et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency. Circulation. 2019; 139(21): 2386–2398.
  47. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017; 29(9): 401–409.
  48. Murphy SP, Kakkar R, McCarthy CP, et al. Inflammation in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(11): 1324–1340.
  49. Kalogeropoulos AP, Tang WH, Hsu A, et al. High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. J Card Fail. 2014; 20(5): 319–326.
  50. Ghafourian K, Chang HC, Ardehali H. Intravenous iron therapy in heart failure: a different perspective. Eur J Heart Fail. 2019; 21(6): 703–714.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl